NCT00249990View on ClinicalTrials.gov

Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC)

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

July 31, 2006

Study Completion Date

September 30, 2007

Conditions
Corpus UteriEndometrial Cancer
Interventions
DRUG

9-NC in aerosol reservoir

Dose: 0.4 mg/ml of 9-NC in aerosol reservoir for 60 minutes (= daily dose of 0.52 mg/m2/day) per day X5 every week, X8 weeks, then observe for 2 weeks. One course = 10 weeks (45-47).

Trial Locations (1)

87131

University of New Mexico, Albuquerque

All Listed Sponsors
collaborator

Baylor College of Medicine

OTHER

lead

University of New Mexico

OTHER

NCT00249990 - Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC) | Biotech Hunter | Biotech Hunter